Adrenergic Antagonist Pipeline Insight
DelveInsight’s, “Adrenergic Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Adrenergic Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adrenergic Antagonists Understanding
Adrenergic Antagonists: Overview
Adrenergic antagonists (adrenoblockers) are compounds that inhibit the action of adrenaline (epinephrine), noradrenaline (norepinephrine), and other catecholamines that control autonomic outflow and some functions of the central nervous system at the adrenergic receptors or inhibit their release. Adrenoblockers are highly effective pharmaceuticals that are used broadly in treatment of cardiac diseases. Their physiological effects include the dilation of blood vessels, which lowers blood pressure and slows heart rate. Two types of adrenoreceptors—α1 and α2—are known. Selective α1 adrenoblockers inhibit the ability of catecholamines to constrict the blood vessels. α2 Adrenoblockers are mainly used in research, finding limited clinical application. β Adrenoblockers are divided into β1, β2, and β3 blockers. Nonselective β blockers usually are classified as first-generation drugs, the cardioselective β1 blockers as second-generation drugs, and the recently discovered β blockers with vasodilator action (selective or nonselective) as third-generation drugs. There are no therapeutically useful selective β2 adrenoblockers.
"Adrenergic Antagonists - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenergic Antagonists pipeline landscape is provided which includes the disease overview and Adrenergic Antagonists treatment guidelines. The assessment part of the report embraces, in depth Adrenergic Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenergic Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Adrenergic Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Adrenergic Antagonists.
Adrenergic Antagonists Emerging Drugs Chapters
This segment of the Adrenergic Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adrenergic Antagonists Emerging Drugs
TNX-102 SL: Tonix Pharmaceuticals
TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. The dose of TNX-102 SL being studied in fibromyalgia is two tablets, or 5.6 mg of cyclobenzaprine each night at bedtime. Tonix is developing TNX-102 SL as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase III clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body's adaptive ability to modulate the perception of pain.
Nyxol: Ocularis Pharma
Nyxol is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist that inhibits the contraction of smooth muscle of the iris. In multiple Phase II trials Nyxol reduced pupil diameter, resulting in better contrast sensitivity and visual acuity. Nyxol is being developed for dim or night vision disturbances (DLD), reversal of pharmacologically-induced mydriasis, and presbyopia. It is currently in Phase III stage of development and is being developed by Ocularis Pharma.
Further product details are provided in the report……..
Adrenergic Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Adrenergic Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adrenergic Antagonists
There are approx. 30+ key companies which are developing the therapies for Adrenergic Antagonists. The companies which have their Adrenergic Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Adrenergic Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Adrenergic Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenergic Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenergic Antagonists drugs.
Adrenergic Antagonists Report Insights
- Adrenergic Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Adrenergic Antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adrenergic Antagonists drugs?
- How many Adrenergic Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenergic Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenergic Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adrenergic Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?